TerminatedNCT00768482
A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence
Medication studyAges 18–75United StatesAddiction
Understand this study
Who could participate?
Listed age limits: 18 years to 75 years.
- Listed locations
- Fort LauderdaleSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateSeptember 2008
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 9
- Sponsor
- Titan Pharmaceuticals
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT00768482
- Official title
Show the full official title
A Single Cross-Over, Open-Label Study of the Relative Bioavailability of Probuphine Versus Buprenorphine Sublingual Tablets at Steady State in Patients With Opioid Dependence
Recruitment & locations
TerminatedFort Lauderdale
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Titan Pharmaceuticals.
Does this study involve medication?
Yes. The study involves medication, including Probuphine (buprenorphine implant) and Sublingual Buprenorphine.
Who can participate?
Listed age limits: 18 years to 75 years.
Is this study still recruiting?
The registry lists this study as terminated.
